Sotagliflozin Lowers A1c, Weight Even in Kidney Impairment
"These findings highlight the importance of considering the effect of kidney function to help inform and tailor treatment decision-making for patients with diabetes and CKD," Belinda Hardin, PharmD, senior director of medical communications and head of field medical at Lexicon, said at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2025.
Sotagliflozin, a novel agent that inhibits sodium-glucose cotransporter (SGLT) 1 as well as SGLT2, was approved by the US Food and Drug Administration (FDA) in 2023 for reducing the risks of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in patients with heart failure, and for preventing these same events in patients with type 2 diabetes, CKD, and other cardiovascular disease risk factors.
The drug is not indicated for diabetes. In 2019, the FDA declined to approve sotagliflozin as adjunctive treatment for type 1 diabetes due to concerns about the increased risk for diabetic ketoacidosis. And in 2024, the agency again turned down Lexicon's application for sotagliflozin as a treatment for people with type 1 diabetes and CKD. The company hasn't sought an indication for sotagliflozin for type 2 diabetes.
Two SGLT2 inhibitors, dapagliflozin (Farxiga) and empagliflozin (Jardiance), have indications for preventing heart failure hospitalizations in patients with heart failure as well as approvals for type 2 diabetes and preservation of renal function.
The new findings, from a meta-analysis of eight double-blind, randomized, placebo-controlled trials, suggest that despite the lack of an indication for treatment of diabetes or obesity, sotagliflozin does result in A1c and body weight lowering across all levels of kidney function. This study is a companion to a previous similarly designed analysis showing that the effects of sotagliflozin on systolic blood pressure were maintained in patients with type 2 diabetes regardless of kidney function. Those findings were presented at the American Heart Association Scientific Session 2024, Hardin told Medscape Medical News .
Asked for comment, session moderator Sara E. Lubitz, MD, associate professor of medicine and endocrine program director at Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, told Medscape Medical News : "This opens my mind more that if there is a heart failure patient with diabetes and we're looking for sugar reduction as well as heart failure protection, [sotagliflozin] is probably just as efficacious as the SGLT2 inhibitors...that have the indication for glucose-lowering, but we're not pulling it out as a first-line [treatment]."
All eight trials in the meta-analysis had similar designs and timeframes and were at least 26 weeks in duration. The patient-level intent-to-treat population data were pooled. Patients were divided into three subgroups based on kidney function:
Subgroup 1: estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73m 2 (N = 2577)
(N = 2577) Subgroup 2: eGFR ≥ 30 to < 60 mL/min/1.73m 2 (N = 1046)
(N = 1046) Subgroup 3: eGFR < 30 mL/min/1.73m2 (N = 271)
Mean patient ages were 60.2 years in subgroup 1, versus 69.3 and 67.1 years, respectively, in subgroups 2 and 3. The treatment groups were sotagliflozin 400 mg (N = 1728), sotagliflozin 200 mg (N = 728), or placebo (N = 1440).
Overall, compared with placebo, A1c was significantly lowered with 200-mg sotagliflozin (less mean squares [LMS] difference, –0.33) and 400 mg (LMS difference, –0.48). Body weight was also reduced (LMS difference, –1.48 and –1.66, respectively).
The effects on both A1c and body weight of both doses were statistically significant for the overall study population and subgroup 1 (normal kidney function). In subgroup 2, the effect on body weight remained significant for both doses, but only the 400-mg dose effect was significant for lowering A1c.
The 400-mg dose produced significant reductions in all kidney function subgroups for both measures except A1c reduction in subgroup 3, although there was still benefit.
Hardin told Medscape Medical News , "This provides us supplemental information with regard to heart failure outcomes, and not directly focusing on whether there's an additive benefit in terms of A1c or an additive lowering of A1c in patients with chronic kidney disease."
Asked about future plans for sotagliflozin, she replied, "I don't think at this point you'll likely see sotagliflozin before the FDA for a glucose-lowering indication in type 2 patients. The file remains open for type 1 at the FDA, so that work continues."
Hardin is an employee of Lexicon. Lubitz is a speaker for Ascendis and has received clinical trial research funding from Ascendis, Chiasma, and Takeda.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
41 minutes ago
- Fox News
Health officials warn of dangerous substance available in stores across the nation
Health officials are taking action against a substance that some are calling "gas station heroin." The FDA is recommending that 7-hydroxymitragynine (also known as 7-OH) — a byproduct of the plant kratom — be classified as a Schedule I drug. HHS Secretary RFK Jr. and FDA Commissioner Dr. Marty Makary emphasized the importance of getting ahead of yet another wave of addiction before it can sweep across the country. Makary compared the distribution of 7-OH to the early days of opioid prescriptions, before doctors understood the addictive nature of painkillers. "Vape stores are popping up in every neighborhood in America, and many are selling addictive products like concentrated 7-OH. After the last wave of the opioid epidemic, we cannot get caught flat-footed again," Makary said in an FDA statement. "7-OH is an opioid that can be more potent than morphine. We need regulation and public education to prevent another wave of the opioid epidemic." During a news conference on Tuesday, Makary suggested that the public health community is often late to act against dangerous substances due to a "disconnect between the ivory towers and the streets." He then pondered aloud if experts had been to vape stores, as it "affects what we see in the operating room." According to the FDA, 7-OH is beginning to be recognized for its potential to be abused because of its ability to bind to opioid receptors. Additionally, the substance is widely available and may be appealing to children and teens as it is sold in fruit-flavored gummies and even ice cream cones. The FDA is also warning that 7-OH products "may not be clearly or accurately labeled as to their 7-OH content and are sometimes disguised or marketed as kratom." "I am in favor of this move because of the relationship of the 7-OH to the opioid receptors. This is essentially an opioid. It is semisynthetic and derived from the kratom plant whose leaves make a stimulant. There are no approved 7-OH drugs or diet supplements," FOX News Senior Medical Analyst Dr. Marc Siegel told Fox News Digital. "Bravo to the FDA for this move — it should be listed as a controlled substance." Kennedy spoke about his own battle with heroin addiction. The HHS secretary described his "iron willpower" and how he gave up candy and desserts for years, making him feel as though he could do anything, until he got his hands on heroin. "I felt that I could do anything with my willpower, but this compulsion was absolutely impervious to my will, and part of the problem was just the availability. It was too easy to get this drug for me," Kennedy said. He also noted that President Donald Trump's family has also grappled with addiction. Though the president has been sober his entire life, his brother, Fred Trump Jr., struggled with alcoholism for much of his life and died at the age of 43. "I had a brother, Fred, great guy," Trump said about his brother in 2017. "But he had a problem. He had a problem with alcohol. And he would tell me, 'Don't drink. Don't drink.'" Trump said at the time that he listened to his brother because he "respected him," adding that "to this day, I've never had a drink." Sen. Markwayne Mullin, R-Okla., who attended the news conference, supported the recommendation based on his family's experience with addiction, though he did not detail exactly to whom he was referring. "It's an addiction that is ruining lives," Mullin said at a Tuesday news conference. He went on to thank Kennedy on behalf of his own family and "every single family that has dealt with this" for acting against the powerful drug. The CDC reported in May that drug overdose deaths in the country dropped in 2024. The U.S. saw "80,391 drug overdose deaths in the United States during 2024 — a decrease of 26.9% from the 110,037 deaths estimated in 2023." Additionally, the CDC found that "overdose deaths involving opioids decreased from an estimated 83,140 in 2023 to 54,743 in 2024." Kratom, the plant from which 7-OH is derived, is a tropical tree native to Southeast Asia. The FDA notes that kratom is often used to self-treat a variety of conditions, such as pain, anxiety and depression. The agency notes that it has not approved any prescription or over-the-counter drug products containing kratom or its two main chemical components: mitragynine and 7-OH.
The Hill
an hour ago
- The Hill
FDA recommends concentrated Kratom be scheduled as illicit substance
The Trump administration is recommending that a compound called 7-OH be scheduled as an illicit drug, Food and Drug Administration Commissioner Marty Makary announced Tuesday. The compound is a concentrated by-product of the Kratom plant whose ground leaves are sold as a dietary supplement to boost energy or provide pain relief. FDA officials said the substance has a 'high risk of addiction' and abuse in concentrated form because of its ability to bind to opioid receptors in the brain. Makary said the agency is urging the Drug Enforcement Agency to classify 7-OH as a Schedule 1 substance, placing it on list of drugs that include heroin, lysergic acid diethylamide (LSD) and ecstasy. 'We have a history in public health of being asleep at the wheel,' Makary said. 'Public health is supposed to prevent disasters, not just clean them up after they've killed thousands and thousands of people.' The American Kratom Association (AKA), a trade group representing the industry, applauded the recommendation to classify 7-OH as a Schedule 1 substance. 'This bold step is a critical milestone in protecting public health and consumer safety from dangerous synthetic products that masquerade as natural kratom,' the AKA said in a statement. A spokesperson for the group said that the FDA's decision shines a light on a 'massive and growing' problem in the kratom marketplace. Earlier this month, the FDA sent warning letters to seven companies regarding allegations that they are illegally marketing 7-OH products as dietary supplements or as a product that can relieve pain or manage anxiety. Department of Health and Human Services officials said during a Tuesday press conference that they have seen a 'disturbing' rise in reports of poisonings and emergency room visits linked to products containing 7-OH which can be found in tablets, gummies, mixed drinks or shots. But officials did not point to data on the scale of the rise in adverse health events. These products are often sold online or in convenience stores, gas stations and vape shops, officials said, with no 'quality control, no dosage control and no warnings.' 'This is a recipe for a public health disaster,' said Jim O'Neil, deputy secretary at the Department of Health and Human Services. 'Young people, veterans and people who suffer from chronic pain or addiction are being misled into thinking that these are safe alternatives. They're not.' Kratom has gained popularity as an alternative pain reliever amid the country's opioid epidemic with some studies suggesting that up to 15 million Americans have use it to treat chronic pain or opioid withdrawal symptoms. In small doses, Kratom can act as a stimulant but can also cause an 'opioid-like' drowsiness and euphoria, experts say. Concentrated Kratom or highly potent Kratom products can cause harmful side effects like nausea, vomiting and even seizures. Tuesday's announcement is the Trump administration's effort to prevent another 'wave of the opioid epidemic' from blindsiding the country, Makaray said. 'There's a lot we don't know. This may be the calm before the storm,' he said. 'It may be the tip of the iceberg, but let's be aggressive and proactive.' The DEA previously announced it would schedule kratom compounds as controlled substances in 2016 but opted not to after receiving intense pushback. Makary stressed that the Trump administration is targeting synthetic, concentrated kratom when asked by a reporter if officials were prepared to deal with similar pushback again.
Boston Globe
an hour ago
- Boston Globe
US health officials crack down on kratom-related products after complaints from supplement industry
The FDA action 'is not focused on natural kratom leaf products,' according to a statement Tuesday by the U.S. Department of Health and Human Services. Advertisement The agency said it was releasing a report to educate about the risks of '7-OH and its distinction from the kratom plant leaf.' Regulators are also recommending that the ingredient be placed on the federal government's most restrictive list of illegal drugs, which includes LSD and heroin. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up '7-OH is an opioid that can be more potent than morphine,' said FDA Commissioner Marty Makary. 'We need regulation and public education to prevent another wave of the opioid epidemic.' The agency's recommendation will be reviewed by the Drug Enforcement Administration, which sets federal rules for high-risk drugs including prescription medicines and illicit substances. A federal ban wouldn't take effect until the agency drafts and finalizes new rules governing the ingredient. Federal regulators have been scrutinizing kratom for about a decade after reports of addiction, injury and overdose. But users and distributors have long opposed efforts to regulate it, saying kratom could be a safer alternative to opioid painkillers that sparked the ongoing drug addiction epidemic. Advertisement Last month, the FDA issued warning letters to seven companies selling drinks, gummies and powders infused with 7-OH. Regulators said the products violated FDA rules because they have not been evaluated for safety and, in some cases, claimed to treat medical conditions, including pain, arthritis and anxiety. Supplement executives quickly applauded the move. The FDA 'demonstrated the exact kind of data-driven, proactive regulatory excellence needed to safeguard unwitting consumers across the U.S.,' said Ryan Niddel of Diversified Botanics, a Utah-based company that sells kratom supplements. An industry group, the American Kratom Association, has lobbied Congress for years against restrictions on the plant. Legislation supported by the group would prohibit the FDA from regulating kratom more strictly than food and dietary supplements Nearly a decade ago, the federal government came close to banning the substance. In 2016, the DEA announced plans to add kratom to the government's most restrictive schedule 1, reserved for drugs that have no medial use and a high potential for abuse. But the plan stalled after a flood of public complaints, including a letter signed by more than 60 members of Congress. The FDA then began studying the ingredient, concluding in 2018 that kratom contains many of the same chemicals as opioids, the addictive class of drugs that includes painkillers like OxyContin as well as heroin and fentanyl. Since then, FDA regulators have continued to issue warnings about cases of injury, addiction and death with kratom supplements, which are usually sold in capsules or powders. Advertisement In recent months, the FDA has also issued warnings on other unapproved drugs sold as supplements or energy drinks, including the antidepressant tianeptine
